Clinical Utility: To identify patients at highest risk for developing lung cancer and then monitor closely to detect lung cancer in its earliest, most treatable stages
Intended For: Patients at highest risk for developing lung cancer based on age and smoking history
Prescribed By: Pulmonologists
Performed In: Multiple CLIA laboratories
Current status: Recruiting patients for clinical trial
Lung cancer remains the most prevalent cause of cancer death in the United States (160,000 deaths each year). A recent NIH-sponsored study determined that annual screening by chest CT scan reduces mortality from lung cancer by more than 20%. However, the annual cost of CT scan screening all 7 million individuals at risk for lung cancer due to age and smoking history exceeds $5 billion. The AccuGenomics Lung Cancer Risk Test promises to identify the individuals genetically pre-disposed to lung cancer so that they can be prioritized for screening. This will markedly reduced cost of CT screening.